From the Journals

Ultraprocessed foods tied to higher risk for CRC, death from heart disease


 

A call to action

Putting it bluntly, “everybody needs food, but nobody needs ultra-processed foods,” Carlos Monteiro, MD, PhD, and Geoffrey Cannon, with University of Sao Paulo, Brazil, write in an editorial in The BMJ.

They point out that most UPFs are made, sold, and promoted by corporations that make them to be convenient, affordable, and hyper-palatable, thus liable to displace other foods and also to be overconsumed.

“The rational solution is official public policies, including guidelines and publicity advising avoidance, and actions, including statutes, designed to reduce production and consumption of ultraprocessed foods and to restrict or preferably prohibit their promotion,” Dr. Monteiro and Mr. Cannon suggest.

What’s also needed, they say, are “available, attractive, and affordable” supplies of fresh and minimally processed foods, as well as national initiatives to promote and support freshly prepared meals made with fresh and minimally processed foods, using small amounts of processed culinary ingredients and processed foods.

“Enacted, this will promote public health. It will also nourish families, society, economies, and the environment,” the editorialists conclude.

The U.S. study was supported by the National Institutes of Health and the Friedman School of Nutrition Science and Policy at Tufts University. The Italian study was supported by the Pfizer Foundation, Italian Ministry of University and Research, Instrumentation Laboratory, Milan, and the Italian Ministry of Health. Dr. Wang, Dr. Song, Dr. Bonaccio, Dr. Monteiro, and Mr. Cannon report no relevant financial relationships.

A version of this article first appeared on Medscape.com.

This article was updated 9/1/22.

Pages

Recommended Reading

Moderate drinking shows more benefit for older vs. younger adults
MDedge Hematology and Oncology
Barrett’s esophagus: AGA screening update ‘goes above and beyond’
MDedge Hematology and Oncology
Higher ADR continues to show ‘strong, consistent’ link with lower interval CRC
MDedge Hematology and Oncology
Patient CRC screening preferences don’t match what they’re being offered
MDedge Hematology and Oncology
New blood test could reshape early CRC screening
MDedge Hematology and Oncology
Can folic acid halt or reverse progression of gastric precancerous conditions?
MDedge Hematology and Oncology
Pervasive ‘forever chemical’ linked to liver cancer
MDedge Hematology and Oncology
Erlotinib promising for cancer prevention in familial adenomatous polyposis
MDedge Hematology and Oncology
Fine-needle aspiration alternative allows closer look at pancreatic cystic lesions
MDedge Hematology and Oncology
New model could boost BE screening, early diagnosis
MDedge Hematology and Oncology